House
Sign inCreate account
Drug lookup
Drug reference

lumacaftor

Cystic fibrosis transmembrane conductance regulator modulator

Cystic fibrosis transmembrane conductance regulator modulator
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
  • AbemaciclibSevereDatabaseDDInter
  • AbirateroneSevereDatabaseDDInter
  • AcalabrutinibSevereDatabaseDDInter
  • AlpelisibSevereDatabaseDDInter

Mechanism

Lumacaftor improves cell surface expression of the most common CFTR variant, ΔF508.

Indications

cystic fibrosis (specifically for patients with the common CFTR variant ΔF508)CF with F508del mutation (in combination)

Drug interactions

Abemaciclib
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Abiraterone
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Acalabrutinib
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Alpelisib
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Amlodipine
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Apixaban
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Apremilast
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Avapritinib
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Axitinib
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Bedaquiline
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Bortezomib
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Bosutinib
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Related guidelines

Empirical antimicrobial use in common syndromes
ICMR · Infectious Diseases · 2019
Pulmonary tuberculosis
RNTCP · Infectious Disease · 2023
MASLD / non-alcoholic fatty liver disease
AASLD · Gastroenterology · 2023
Dyslipidaemia in diabetes
RSSDI · Endocrinology · 2022
Hepatitis C — chronic infection
EASL · Gastroenterology · 2020

Other Unclassified drugs

5-9-tetrahydrocannabinol
0 brands
6-mercaptopurine
0 brands
acetylsalicylic acid
0 brands
acotiamide
0 brands
acoziborole
0 brands
activated charcoal
0 brands
adrenaline
0 brands
adrenochrome monosemicarbazone
0 brands

Ask House about lumacaftor

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspaceAsk House about this drug

Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team